Literature DB >> 19891962

The serotonin transporter promoter polymorphism (5-HTTLPR) is associated with type 2 diabetes.

Maria Iordanidou1, Anna Tavridou, Ioannis Petridis, Kostas I Arvanitidis, Dimitrios Christakidis, Vassilios Vargemezis, Vangelis G Manolopoulos.   

Abstract

BACKGROUND: The serotonergic system contributes substantially to the regulation of glucose homeostasis and feeding. 5-HTTLPR is a serotonin transporter (5-HTT) gene-linked polymorphic region that regulates the transcriptional activity of 5-HTT. Our aim was to investigate the possible association of 5-HTTLPR polymorphism with type 2 diabetes mellitus and obesity.
METHODS: Study population consisted of 252 subjects diagnosed with Type 2 DM and 211 non-diabetic subjects, all Caucasians of Greek ethnic origin. Genomic DNA was extracted from peripheral blood and analyzed for 5-HTTLPR polymorphism with a novel PCR protocol.
RESULTS: The frequency of SS and SL genotypes of HTTLPR was significantly higher in the diabetic group (77.0%) than in the non-diabetic group (61.6%) (P<0.001). The genetic risk of Type 2 DM for subjects carrying at least one S allele was increased compared to non-diabetic subjects (OR=2.08, 95% CI=1.39-3.12). When subjects were divided according to BMI status, the frequency of S allele carriers was similar in obese and non-obese subjects.
CONCLUSIONS: The S allele of 5-HTTLPR is strongly associated with the presence of Type 2 DM. This association appears to be direct and not dependent on obesity status. Therefore, 5-HTTLPR LL genotype might be protective for development of Type 2 DM. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19891962     DOI: 10.1016/j.cca.2009.10.022

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  19 in total

1.  Association of MAOA, 5-HTT, and NET promoter polymorphisms with gene expression and protein activity in human placentas.

Authors:  Huiping Zhang; Graeme N Smith; Xudong Liu; Jeanette J A Holden
Journal:  Physiol Genomics       Date:  2010-03-23       Impact factor: 3.107

2.  Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels.

Authors:  N P Tatonetti; J C Denny; S N Murphy; G H Fernald; G Krishnan; V Castro; P Yue; P S Tsao; P S Tsau; I Kohane; D M Roden; R B Altman
Journal:  Clin Pharmacol Ther       Date:  2011-05-25       Impact factor: 6.875

3.  Genetic modulation of the serotonergic pathway: influence on weight reduction and weight maintenance.

Authors:  Dirk Wallmeier; Julia K Winkler; Thomas Fleming; Annika Woehning; Katharina Huennemeyer; Eva Roeder; Peter P Nawroth; Hans-Christoph Friederich; Christian Wolfrum; Jobst-Hendrik Schultz; Gottfried Rudofsky
Journal:  Genes Nutr       Date:  2013-06-25       Impact factor: 5.523

Review 4.  The role of prolactin in andrology: what is new?

Authors:  Giulia Rastrelli; Giovanni Corona; Mario Maggi
Journal:  Rev Endocr Metab Disord       Date:  2015-09       Impact factor: 6.514

5.  Association of a serotonin transporter gene (SLC6A4) 5-HTTLPR polymorphism with body mass index categories but not type 2 diabetes mellitus in Mexicans.

Authors:  Valeria Peralta-Leal; Evelia Leal-Ugarte; Juan P Meza-Espinoza; Ingrid P Dávalos-Rodríguez; Anabel Bocanegra-Alonso; Rosa I Acosta-González; Enrique Gonzales; Saraswathy Nair; Jorge Durán-González
Journal:  Genet Mol Biol       Date:  2012-07-26       Impact factor: 1.771

6.  Promoter methylation of serotonin transporter gene is associated with obesity measures: a monozygotic twin study.

Authors:  J Zhao; J Goldberg; V Vaccarino
Journal:  Int J Obes (Lond)       Date:  2012-01-31       Impact factor: 5.095

7.  Serotonin and the bone assessment.

Authors:  M Carsote; V Radoi; A Geleriu; A Mihai; D Ferechide; D Opris; D Paun; C Poiana
Journal:  J Med Life       Date:  2014

8.  Association of Plasma Adiponectin and Oxidized Low-Density Lipoprotein with Carotid Intima-Media Thickness in Diabetic Nephropathy.

Authors:  Anna Tavridou; Anastasia Georgoulidou; Athanasios Roumeliotis; Stefanos Roumeliotis; Efstathia Giannakopoulou; Nikolaos Papanas; Ploumis Passadakis; Vangelis G Manolopoulos; Vassilis Vargemezis
Journal:  J Diabetes Res       Date:  2015-05-12       Impact factor: 4.011

9.  The serotonin and the bone assessment.

Authors:  M Carsote; V Radoi; A Geleriu; A Mihai; D Ferechide; D Opris; D Paun; C Poiana
Journal:  J Med Life       Date:  2013-06-25

Review 10.  Advances in Medications and Tailoring Treatment for Alcohol Use Disorder.

Authors:  Chamindi Seneviratne; Bankole A Johnson
Journal:  Alcohol Res       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.